Information Provided By: 
Fly News Breaks for July 25, 2019
ANIK
Jul 25, 2019 | 05:44 EDT
First Analysis analyst Joseph Munda double upgraded Anika Therapeutics to Strong Buy from Neutral and raised his price target for the shares to $54 from $37. The analyst sees further share price appreciation potential beyond the 10% after-hours increase following the company's better than expected Q2 results and outlook. He highlights better U.S. pricing for Orthovisc and Monovisc and the company's "highly anticipated" inaugural analyst day in mid-September.
News For ANIK From the Last 2 Days
There are no results for your query ANIK
